Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00707694 · ClinicalTrials.gov registry record
The Longevity Genes in Founder Populations Project
A clinical trial of Extreme Longevity, sponsored by Albert Einstein College of Medicine.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 2
- Study locations
NCT00707694 is a study of Extreme Longevity that is actively recruiting participants, run by Albert Einstein College of Medicine. The registered enrollment target is 2,000 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT00707694, a study of Extreme Longevity, is actively recruiting participants, sponsored by Albert Einstein College of Medicine.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.
Conditions Studied
Study Locations (2)
New York
- Private Homes - New York
- Hebrew Home Riverdale - Riverdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 1998-07 |
| Est. Completion | 2032-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00707694
The ClinicalTrials.gov registry entry for NCT00707694 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extreme Longevity appearing as the primary indexed condition, and to 0 interventions.
NCT00707694 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00707694 about?
NCT00707694 is a clinical study titled "The Longevity Genes in Founder Populations Project". We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replic...
What is the current status of trial NCT00707694?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 1998-07. Estimated completion is 2032-12.
What conditions does trial NCT00707694 study?
This clinical trial studies the following conditions: Extreme Longevity.
Who is sponsoring clinical trial NCT00707694?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00707694 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.